Researchers from the Rey Juan Carlos University and PSL University of Paris have developed a new photosensitizing agent for nanoparticles of silica and ruthenium. Medicines of this type are activated by light when they are within the cancer cells and favor their elimination of less aggressive photodynamic therapy for the patient.
The study deals with mesoporous silica nanoparticles of size less than 80 nanometers with a routine derivative. / URJC
The use of metal-based drugs, chemotherapeutic properties and metal compounds for the treatment of cancer is of particular interest in patients with different tumors. It is estimated that approximately 60% of all cancer patients have been treated with metal compounds, mainly platinum, at least once during the course of the disease.
However, these metal compounds have several problems with their therapeutic use due to their large number of side effects and the possibility of tumor becoming resistant. In addition, they cause solubility problems in biological media and limitations to doses that may be administered to certain patients with problems with tumor progression in the immune system.
The development of new nanoformulations in the use of various less aggressive therapies, such as light dynamics, is one of the research teams in the Reet Juan Carlos University's COMET-NANO Group. "These treatments are based on photosensitizers that, after certain light sources that are exposed to specific properties, produce a specific oxygen that is capable of acting on their cancer cells, leading to death," says Santiago Gómez-Ruiz, a researcher at the COMET-NANO Group.
Photodynamic agents are therefore used for photodynamic treatment. When cancer cells absorb them and are exposed to light, the drug is activated and destroys cancer cells.
The most recent work of this team in this field is to formulate in mesoporous silica nanoparticles of less than 80 nanometers together with a derivative of ruthenium (ru, a metal with low toxicity) having photodynamic activity in UV-A light. "Our goal is to explore the potential of these ruthenium nanomaterials systems and the like in the photodynamic treatment of different tumors," Gómez-Ruiz says.
This work is the result of cooperation with Professor Gilles Gasser (ERC Consolidator) Chimie ParisTech PSL Université Paris (France) and the University of Zurich (Switzerland). It has been published in the journal Dalton Transactions, in addition to having been published in a special publication "Bioinspired Reactivity of Coordination Compounds".
Innovative Medicines and Future Clinical Trials
Nowadays, there is only one formulation of the ruthenium compound studied in clinical studies by Mc Farland (UNC Greensboro, USA), a TLD-1433. URJC and PSL Université Paris researchers have shown that the nanoformulation of the studied ruthenium metal line improves the outcome of cell death in cancer cells after the use of light and opened the door for future clinical studies of this type of therapeutic compounds.
As in Santiago Gómez-Ruiz, progress is made: "In this paper, we focus on drugs that can be activated with less energetic and more comfortable light than UV-A, such as red or infrared light, which would give them excellent candidates for direct access to certain therapeutic interest tumors at this time."